In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.

Latest From Akriti Seth

Teva Launches First Generic Of Sun’s Absorica In US

Teva has launched the first US generic version of Absorica (isotretinoin), expanding its dermatological portfolio. The company has also launched generic erythromycin tablets in the US. Meanwhile, in its recent environmental, social and governance progress report, Teva has launched a plan to increase access to medicines globally by 2025.

United States Generic Drugs

Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake

Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled. 

Sales & Earnings Vaccines

Laurus Labs Expands Capacity To Meet API Demand

Laurus Labs has reported a 70% jump in annual revenues after what the company described as an “extraordinary year.” The firm has decided to expand its current capacities to meet the increased demand for third-party API sales and is looking to file eight to ten ANDAs next year as it sees “many long-term opportunities in the US generics space.”

Generic Drugs Strategy

Beximco’s Global Expansion Leads To Export Rise

Bangladesh’s Beximco has reported growth in export sales on the back of the company’s expansion into new international markets. The company delivered strong financial results overall for the third quarter of fiscal 2021, including double-digit growth on the domestic front. 

Strategy Sales & Earnings

Former FDA Official Criticizes COVID-19 Guidance’s Silence On Biosimilars

Former senior FDA official Eva Temkin has criticized the FDA’s silence on the development of biosimilars and interchangeable products in its recent COVID-19 guidance, suggesting that the agency’s stance on 180-day exclusivity for small-molecule generics could be extended to interchangeability exclusivity for biosimilars, while also pointing out that key questions around generic exclusivity are left unanswered

FDA Biosimilars

IPA’s Jain Predicts 3-4 Weeks To Meet Indian Shortages

Speaking exclusively to Generics Bulletin, Indian Pharmaceutical Alliance secretary general Sudarshan Jain says that India’s needs for COVID drugs like favipiravir, remdesivir and tocilizumab will be met “in the near future.” Current IGBA chair Jain also talks about global collaboration by governments and donors for equal vaccine distribution through the Access to COVID-19 Tools Accelerator.

India Coronavirus COVID-19
See All
UsernamePublicRestriction

Register